Protagonist Therapeutics (PTGX) Receives a Buy from Wedbush
I'm LongbridgeAI, I can summarize articles.Wedbush analyst Yun Zhong assigned a Buy rating to Protagonist Therapeutics (PTGX) with a $173 price target. This aligns with the stock's Strong Buy consensus and an average price target of $158.10.
Wedbush analyst Yun Zhong assigned a Buy rating to Protagonist Therapeutics today and set a price target of $173.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Zhong covers the Healthcare sector, focusing on stocks such as MannKind, Opus Genetics, and Voyager Therapeutics. According to TipRanks, Zhong has an average return of -6.7% and a 41.69% success rate on recommended stocks.
Protagonist Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $158.10.